IP Library Granted Patent US 10,196,403
Granted Patent B2
US 10,196,403 · App. 15/663,688 · Granted Feb 5, 2019

Compounds and compositions and uses thereof

Inventors: Taleen G. Hanania (Valhalla, NY); Michele L. R. Heffernan (Holliston, MA); Philip Glyn Jones (Danvers, MA); Linghong Xie (Southborough, MA)
Assignees: Sunovion Pharmaceuticals Inc.; PGI Drug Discovery LLC
C07D493/04C07D307/87C07D311/76C07D313/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,196,403
App. No.
15/663,688
Granted
Feb 5, 2019
Kind
B2
Abstract

Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Claims (49)

1. A compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof.

2. A compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof.

3. A method of treating a neurological or psychiatric disease or disorder selected from bipolar disorder, anxiety, depression, Alzheimer's Disease with agitation, Alzheimer's Disease with aggression or Alzheimer's Disease with agitation aggression in a subject in need thereof, comprising administering to said subject an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof.

4. A method of treating bipolar disorder in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

5. A method of treating anxiety in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

6. A method of treating depression in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

7. A method of treating Alzheimer's Disease with agitation in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

8. A method of treating Alzheimer's Disease with aggression in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

9. A method of treating Alzheimer's Disease with agitation aggression in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 2 , wherein said compound is greater than 90% enantiomerically pure.

11. The compound according to claim 2 , wherein said compound is greater than 95% enantiomerically pure.

12. A compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 12 , wherein said compound is greater than 90% enantiomerically pure.

14. The compound according to claim 12 , wherein said compound is greater than 95% enantiomerically pure.

15. A compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 15 , wherein said compound is greater than 90% enantiomerically pure.

17. The compound according to claim 15 , wherein said compound is greater than 95% enantiomerically pure.

18. A compound, wherein said compound is:

19. The compound according to claim 18 , wherein said compound is greater than 90% enantiomerically pure.

20. The compound according to claim 18 , wherein said compound is greater than 95% enantiomerically pure.

21. A compound, wherein said compound is:

22. The compound according to claim 21 , wherein said compound is greater than 90% enantiomerically pure.

23. The compound according to claim 21 , wherein said compound is greater than 95% enantiomerically pure.

24. A pharmaceutical composition comprising the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

25. A pharmaceutical composition comprising the compound according to claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

26. A pharmaceutical composition comprising the compound according to claim 12 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

27. A pharmaceutical composition comprising the compound according to claim 15 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

28. A pharmaceutical composition comprising the compound according to claim 18 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

29. A pharmaceutical composition comprising the compound according to claim 21 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

30. A method of treating Alzheimer's Disease in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

31. A method of treating bipolar disorder in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

32. A method of treating anxiety in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

33. A method of treating depression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

34. A method of treating Alzheimer's Disease in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

35. A method of treating Alzheimer's Disease with agitation in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

36. A method of treating Alzheimer's Disease with aggression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

37. A method of treating Alzheimer's Disease with agitation aggression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

38. A method of treating bipolar disorder in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15 , or a pharmaceutically acceptable salt thereof.

39. A method of treating anxiety in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15 , or a pharmaceutically acceptable salt thereof.

40. A method of treating depression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15 , or a pharmaceutically acceptable salt thereof.

41. A method of treating Alzheimer's Disease in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15 , or a pharmaceutically acceptable salt thereof.

42. A method of treating Alzheimer's Disease with agitation in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15 , or a pharmaceutically acceptable salt thereof.

43. A method of treating Alzheimer's Disease with aggression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15 , or a pharmaceutically acceptable salt thereof.

44. A method of treating Alzheimer's Disease with agitation aggression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15 , or a pharmaceutically acceptable salt thereof.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Nov 8, 2023
From: SUNOVION PHARMACEUTICALS INC.; SUMITOMO PHARMA AMERICA, INC.
To: SUMITOMO PHARMA AMERICA, INC.
Reel/Frame 065519/0101 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2018
From: HANANIA, TALEEN G.
To: PGI DRUG DISCOVERY LLC
Reel/Frame 045080/0134 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2018
From: HEFFERNAN, MICHELE L.R.; JONES, PHILIP GLYN; XIE, LINGHONG
To: SUNOVION PHARMACEUTICALS INC.
Reel/Frame 044954/0436 →
Continuity (2)
Provisional Application 62368526 · Jul 29, 2016
Related Publication 20180030064A1 · Feb 1, 2018